Oral semaglutide absorption shows considerable inter-individual variability in clinical practice. A retrospective cohort study published in Diabetes, Obesity and Metabolism evaluated whether estimated individual drug exposure provided predictive information beyond prescribed dose alone.

The analysis included 256 adults with type 2 diabetes (T2D) initiating oral semaglutide therapy. Participants had a mean age of 65.6 years, and 31.6% were women. A validated population pharmacokinetic model incorporating dose, weight, sex, ethnicity, and gastrointestinal (GI) disorders was used to estimate average semaglutide exposure (eCavg) at each follow-up visit.

Findings

• Mean glycated hemoglobin (HbA1c) decreased by 0.7% during follow-up, while body weight declined by 7.5%.

• GI side effects were reported in 41.8% of participants.

• Both prescribed dose and eCavg were significantly associated with glycemic response, weight loss, and GI side effects when analyzed individually.

• The dose-based model outperformed the eCavg model for predicting HbA1c changes (p<0.01).

• The eCavg model showed modestly improved fit for weight loss outcomes (p<0.001).

• The exposure-effect relationship appeared right-shifted for weight loss compared with glycemic response. 

Estimated oral semaglutide exposure provided additional predictive information for weight loss and GI side effects beyond prescribed dose alone, whereas prescribed dose appeared sufficient to predict glycemic response.